Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Caplin Point Laboratories subsidiary gets FDA final approval for Thiamine Hydrochloride Injection Caplin Point Laboratories said that its subsidiary Caplin Steriles has secured final approval for its abbreviated new drug… byPallavi MadhirajuMarch 9, 2023